Similarly, to the scenario observed for WWTR1, high TOGARAM2 expression correlated with reduced progression-free survival specifically in HPV18+ cervical cancer patients, but this did not reach statistical significance (Fig. 7H, I). Here, TOGARAM2 is linked to cervical carcinoma.